Product Description
Mechanisms of Action: Sirt1 Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sirtris
Company Location: CAMBRIDGE MA 02139
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Psoriasis|Type 2 Diabetes
Phase 1: Type 2 Diabetes|Chronic Obstructive Pulmonary Disease|Muscular Atrophy|Sepsis|Psoriasis|Colitis, Ulcerative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01453491 | P1 |
Completed |
Colitis, Ulcerative |
2013-03-18 |
|
NCT01702493 | P1 |
Completed |
Psoriasis |
2012-12-05 |
|
NCT01154101 | P2 |
Completed |
Psoriasis |
2011-11-09 |
|
NCT01031108 | P1 |
Completed |
Type 2 Diabetes |
2011-10-12 |